Astraveus has entered into a partnership with the Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen).
Together, the companies will evaluate Astraveus' Lakhesys Benchtop Cell Factory to demonstrate its potential in boosting the efficiency and cost-effectiveness of CAR-T therapy manufacturing.
Under the terms of the agreement, NecstGen will utilise Astraveus’ unique Lakhesys Benchtop Cell Factory at its facility in Leiden, where the company will produce lentiviral vectors for Astraveus' internal R&D needs.
The Lakhesys Benchtop Cell Factory was recently responsible for the first ever, end-to-end production of CAR-T cells within a microfluidic benchtop system, with the Astraveus now rolling out external tasting for the platform.
"NecstGen and Astraveus share a common passion and determination to deliver next-generation cell and gene therapies with increased accessibility and affordability," noted Jérémie Laurent, PhD, CEO of Astraveus.
"This partnership, with a leading European center of excellence for Cell and Gene Therapy, enables Astraveus to carry out external system demonstrations of our disruptive Lakhesys platform technology in a highly collaborative and transparent manner."
"We are impressed by the deep expertise, commitment and enthusiasm of NecstGen to tackle today’s constraints in cell therapy manufacturing, and we look forward to the forthcoming benefits of this partnership.”
“At NecstGen, we partner with leading innovators to deliver next-generation therapeutics for patients. Astraveus’ novel approach to the manufacturing of CAR-T cells represents a breakthrough technology with the ability to transform the industry by enabling the faster and cheaper development of these cutting-edge treatments,” concluded Paul Bilars, CEO of NecstGen.